Figure 3.

The study patients were categorized on the basis of whether they had a Log adiponectin level at 3 months higher or lower than the median value of 3.91 ng/mL and a Log NT-proBNP level at 3 months higher or lower than the median baseline level of 2.64 pg/mL. Fourty-eight of the 124 patients (39%) had no elevation in either adiponectin or NT-proBNP (Group 1); 28 (22%) had elevation in one (Group 2); and 48 (39%) had elevations in two (Group 3). The difference in event-free survival curves among the 3 groups was significant.